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Abstract
Background: ADAMTS13 is the physiological von Willebrand factor (VWF)-cleaving protease. The aim of this study was to
examine ADAMTS13 expression in kidneys from ADAMTS13 wild-type (Adamts13+/+) and deficient (Adamts132/2) mice and
to investigate the expression pattern and bioactivity in human glomerular endothelial cells.
Methodology/Principal Findings: Immunohistochemistry was performed on kidney sections from ADAMTS13 wild-type
and ADAMTS13-deficient mice. Phenotypic differences were examined by ultramorphology. ADAMTS13 expression in
human glomerular endothelial cells and dermal microvascular endothelial cells was investigated by real-time PCR, flow
cytometry, immunofluorescence and immunoblotting. VWF cleavage was demonstrated by multimer structure analysis and
immunoblotting. ADAMTS13 was demonstrated in glomerular endothelial cells in Adamts13+/+ mice but no staining was
visible in tissue from Adamts132/2 mice. Thickening of glomerular capillaries with platelet deposition on the vessel wall was
detected in Adamts132/2 mice. ADAMTS13 mRNA and protein were detected in both human endothelial cells and the
protease was secreted. ADAMTS13 activity was demonstrated in glomerular endothelial cells as cleavage of VWF.
Conclusions/Significance: Glomerular endothelial cells express and secrete ADAMTS13. The proteolytic activity could have
a protective effect preventing deposition of platelets along capillary lumina under the conditions of high shear stress
present in glomerular capillaries.
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Introduction
The known substrate for ADAMTS13 (a disintegrin-like and
metalloprotease with thrombospondin type-1 motifs) is von
Willebrand Factor (VWF) [1], a glycoprotein, that induces platelet
adhesion and aggregation at sites of vascular injury and high-shear
stress [2]. VWF is produced in endothelial cells [3] and
megakaryocytes [4] and secreted from endothelial cells as ultra-
large multimers (ULVWF) [5], which are biologically very active
[2,6].
ULVWF multimers are cleaved on the surface of endothelial
cells into smaller multimers by ADAMTS13 [7]. ADAMTS13
cleaves the 1605Tyr-1606Met peptide bond in the A2 domain of
VWF thereby releasing 140 kDa and 176 kDa VWF fragments
[8]. Apart from ADAMTS13, four other proteases, elastase,
proteinase 3, cathepsin G and matrix metalloprotease 9 (MMP9),
have been shown to cleave VWF at sites identical with, or near,
the ADAMTS13 cleavage site [9]. ADAMTS13 is, however,
considered most important for cleavage of VWF under
physiological conditions and conditions of increased shear stress
[7].
Deficient ADAMTS13 activity leads to thrombotic thrombocy-
topenic purpura (TTP) [10] which may either be the result of
mutations in the ADAMTS13 gene (congenital TTP) [11] or due
to the presence of auto-antibodies against ADAMTS13 (acquired
TTP) [12]. TTP is characterized by thrombocytopenia, microan-
giopathic hemolytic anemia, fever, renal and neurological
manifestations. Due to lack of or dysfunction of ADAMTS13,
the degradation of ULVWF is impaired which leads to the
formation of disseminated platelet thrombi, a characteristic feature
of TTP [10].
ADAMTS13 has been found to be synthesized by hepatic stellate
cells [13], endothelial cells [14,15] and megakaryocytes [16,17], as
well as other cells. The kidney has been shown to express
ADAMTS13 mRNA [11,18]. As the kidney is one of the main
organs affected during TTP, our group has studied renal expression
of ADAMTS13. ADAMTS13 was demonstrated in situ in the renal
cortex [19]. ADAMTS13 expression was detected at both the
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mRNA and protein level in cultured podocytes and tubular cells and
its bioactivity was demonstrated in both cell types [19,20].
ADAMTS13 cleaves ULVWF multimers on the surface of
endothelial cells under flow conditions mimicking the bloodstream
[7]. This form of cleavage would be of utmost importance in the
presence of high shear stress such as in glomerular capillaries.
Deficient ADAMTS13 or dysfunctional protease activity would
presumably allow deposition of ULVWF and platelets on
glomerular capillary walls contributing to the development of
thrombotic microangiopathy. ADAMTS13-deficient mice (with
the 129X1/SvJ and C57BL/6J genetic background) did not
develop TTP-like pathology spontaneously but, upon introduction
of the CASA/Rk background, were shown to develop TTP-like
pathology after endothelial cell injury was induced by Shiga toxin
[21].
The purpose of the present study was to investigate glomerular
endothelial ADAMTS13 expression and phenotype using renal
tissue from wild-type and ADAMTS13-deficient mice and to study
the effect of ADAMTS13 deficiency on glomerular capillary walls
and platelet deposition. Furthermore, in vitro studies were
designed to demonstrate ADAMTS13 expression and activity in
human glomerular endothelial cells.
Results
ADAMTS13 expression in mouse kidney
Immunohistochemistry performed on renal tissue from
Adamts13+/+ wild-type mice exhibited positive staining in glomer-
ular endothelial cells (Figure 1A) as well as in podocytes and tubuli.
No staining was visible in tissue from the Adamts132/2 mice
(Figure 1B). The control antibodies did not label mouse tissue (data
not shown). No signal was detected when the primary antibodies
were omitted (data not shown).
Altered vessel phenotype in ADAMTS13-deficient mice
In order to assess if lack of ADAMTS13 affected the vessel wall,
renal samples from Adamts13+/+ (Figure 2A, C, E) and Adamts132/2
(Figure 2B, D, F) mice (from two independent genetic backgrounds)
were examined by scanning electron microscopy. Glomeruli from
Adamts13+/+ wild-type mice exhibited patent capillaries with smooth
vessel walls and thin basement membranes as shown in Figure 2A
and 2C. Glomeruli from Adamts132/2mice exhibited thickened and
irregular vessel walls (Figure 2B and 2D). This method could not
differentiate between intimal proliferation and thickening of the
glomerular basement membrane both of which could explain this
finding. Uneven surfaces inside the vessel wall suggested protein
deposition. In comparison to Adamts13+/+ mice, Adamts132/2 mice
exhibitedmore platelet deposits in glomerular capillaries (Figures 2E
and 2F, respectively) suggesting that lack of ADAMTS13
contributed to platelet binding to the capillary walls. To quantify
platelet deposition in the glomerular capillaries immunoelectron
microscopy was performed using an antibody against the platelet
marker integrin-b3. Platelet deposition appeared as bright labeling
(insets in Figure 2F). The control antibody showed no staining (data
not shown).
Vessel wall thickness and platelet deposition on glomerular
capillary walls were quantified and compared between Adamts13+/+
and Adamts132/2 mice showing that Adamts132/2 mice had
significantly thicker capillary walls and more platelet deposits, as
presented in Table 1.
ADAMTS13 mRNA expression in endothelial cells
Real-time PCR was applied to investigate if glomerular
endothelial cells CiGEnC synthesize ADAMTS13. HMVEC were
studied as an endothelial cell control. ADAMTS13 mRNA was
detected in CiGEnC and HMVEC (Figure 3) but not in CHO
cells used as the negative control. Human kidney pool and human
liver, which have previously been shown to express ADAMTS13
mRNA [20] were used as positive controls. No-template control
did not show any amplification (Figure 3A). 18S rRNA was used as
an endogenous control and showed comparable levels of
expression in all samples. Results in Figure 3B are presented as
the ratio of ADAMTS13/18S.
ADAMTS13 expression in cultured endothelial cells
ADAMTS13 was detected in both CiGEnC and HMVEC by
flow cytometry analysis of cells permeabilized with Triton X-100.
In CiGEnC both the monoclonal anti-ADAMTS13 A10 antibody
and the polyclonal SU19 antibody bound to 99% of the
population indicating that the entire population was positive for
ADAMTS13 expression (Figure 4A and 4B, respectively). No
labeling was demonstrated using the control antibodies (Figure 4C
and 4D). Similar results were demonstrated for the HMVEC cells
(Figures 4E–4H) and even here most of the labeling was
intracellular. No signal was detected when the primary antibodies
were omitted (data not shown).
Figure 1. ADAMTS13 expression in mouse kidney. ADAMTS13 expression was investigated by immunohistochemistry in mouse renal tissue.
Staining was observed in the kidney of Adamts13+/+ wild-type mice on the mixed 129X1/SvJ and C57BL/6 genetic background (Panel A). The inset in
panel A shows glomerular capillary staining (arrow) at a higher magnification. Tissue from Adamts132/2 mice (same genetic background) did not
label for ADAMTS13 (Panel B). Reproducible results were obtained in six separate experiments including mice with the mixed C57BL/6J and CAST/Ei
genetic background. Images are at 1000x magnification. P: podocyte, US: urinary space, T: tubular cell.
doi:10.1371/journal.pone.0021587.g001
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ADAMTS13 expression in endothelial cells was further
investigated by immunofluorescence. ADAMTS13 protein was
detected intracellularly in permeabilized CiGEnC using the
monoclonal and the polyclonal antibodies. Results using the
polyclonal anti-ADAMTS13 antibody are presented in Figure 5A.
Pre-incubation with blocking peptide markedly reduced signal
intensity of the polyclonal antibody (Figure 5B). Similar results
were observed with the HMVEC cells (Figures 5C–5D).
Figure 2. Ultramorphology of glomeruli in wild-type and deficient mice. Scanning electron microscopy of kidney from wild-type mice
showed normal morphology as depicted in panel A. In the renal glomeruli the Bowman’s capsule (BC), glomerular basement membrane (GBM),
endothelial cell capillaries (C), erythrocytes (E), podocytes (P) and urinary space (US) were identified. Panel B shows a glomerulus from an Adamts132/2
mouse demonstrating thickened and irregular capillary walls (arrow). These findings were enlarged in panel C from another glomerulus from an
Adamts13+/+mouse showing thin glomerular capillary walls (arrow heads) and in panel D from an Adamts132/2mouse showing thickened capillary walls
(arrows) with deposits on the vessel lumina. Panel E demonstrates lack of platelet deposits in glomerular capillaries from an Adamts13+/+mouse, further
confirmed by immunoelectron microscopy (insets). Panel F was taken from another glomerulus in an Adamts132/2 mouse and shows platelets (within
circles) deposited on a vessel wall. Insets in panel F show immunoelectron microscopy with labeled platelets (arrows) deposited on glomerular capillary
walls. Scale bar represents 10 mm (A, B), 5 mm (C–F) and 2.5 mm (insets in E, F). Panels A, B, D–F and insets were frommice with the 129X1/SvJ and C57BL/
6 genetic background and panel C was from mice with the C57BL/6J and CAST/Ei genetic background.
doi:10.1371/journal.pone.0021587.g002
Table 1. Vessel wall thickness and platelet deposition in glomerular capillaries of Adamts13+/+ and Adamts132/2 mice.
Adamts13+/+ mice (n =5) Adamts132/2 mice (n =5) P value
Capillary wall thickness (mm)a, b 0.5 (0.320.8) 1.2 (0.222.3) 0.005d
Platelet deposits/mm2 a, c 51 (41259) 890 (8002981) 0.007d
amedian and (range). bAssessed by quantifying capillary walls in 30 glomerular profiles from each mouse. cAssessed by counting the number of labeled platelets in all
visible vessels in 30 glomerular profiles from each mouse. dFor each mouse a median value was obtained. Medians of five mice in each group were compared
statistically.
doi:10.1371/journal.pone.0021587.t001
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Comparable results were obtained using the monoclonal anti-
ADAMTS13 antibody (data not shown). Omission of the primary
antibodies resulted in lack of signal (data not shown).
ADAMTS13 in the media from both endothelial cells was
detected by immunoblotting. Purified recombinant human
ADAMTS13 was used as the positive control showing a band at
150 kDa (Figure 6, lane 1). A band was not detected in the control
media (Figure 6, lane 2). Media from both CiGEnC and HMVEC
cells revealed bands at approximately 150 kDa (Figure 6, lanes 3
and 4, respectively).
ADAMTS13 activity in endothelial cells
The VWF cleavage activity of ADAMTS13 in both endothelial
cells was demonstrated by VWF multimer structure analysis. Cell
buffer did not exhibit any cleavage and exogenously added VWF
exhibited typical multimers (Figure 7, lanes 1 and 3). In the
presence of CiGEnC and HMVEC lysates almost complete
breakdown of VWF multimers was demonstrated (Figure 7, lanes
2 and 4, respectively).
Cleavage specificity of ADAMTS13
ADAMTS13 cleaves VWF in the A2 domain at the 1605Tyr-
1606Met peptide bond thereby releasing 140 kDa and 176 kDa
fragments [8]. To investigate cleavage specificity, cell lysates and
media were incubated with or without VWF and immunoblotting
was carried out using anti-VWF antibodies specific for the
cleavage products. Recombinant ADAMTS13 incubated with
VWF (as the positive control) cleaved VWF as expected to
176 kDa and 140 kDa fragments (Figure 8A lane 1) whereas cell
buffer incubated with VWF showed only the full-length VWF
(Figure 8A, lane 2). CiGEnC cell lysate exhibited cleavage bands
(Figure 8A, lane 3) similar to those induced by rADAMTS13. This
cleavage was inhibited by pre-incubation with EDTA suggesting
that the cleaving enzyme was a metalloprotease (Figure 8A, lane
4). Similar results were obtained with HMVEC cell lysates
showing the two cleaved VWF fragments (Figure 8A, lane 5)
and marked inhibition by pre-incubation with EDTA (Figure 8A,
lane 6).
As the protease inhibitor used could inhibit all proteases, except
metalloproteases, the data presented above indicated that the
endothelial cell lysates contained a metalloprotease capable of
cleaving VWF. To show that the cleaving activity could be
specifically ascribed to ADAMTS13 the lysates were immunoad-
sorbed using anti-ADAMTS13 antibody. As a positive control
rADAMTS13 showed cleavage of VWF (Figure 8B lane 1) which
was inhibited by immunoadsorption of ADAMTS13 (Figure 8B,
lane 2). Similarly, the lysate from CiGEnC exhibited VWF
cleaving activity (Figure 8B, lane 3) which was markedly reduced
by immunoadsorption of ADAMTS13 (Figure 8B, lane 4). Similar
results were obtained using HMVEC cell lysates (data not shown).
CiGEnC lysate, to which exogenous VWF was not added,
exhibited a weak band at approximately 270 kDa corresponding
to full-length VWF (Figure 8C lane 2) but did not exhibit VWF
cleavage products. Cell media, to which exogenous VWF was not
added, also showed a weak band corresponding to full-length
VWF and lack of VWF cleavage activity (data not shown). Similar
results were obtained using the lysates and media of HMVEC
without addition of exogenous VWF (data not shown). Thus the
demonstrated VWF cleavage in cell lysates occurred in exoge-
nously added VWF.
Media from CiGEnC incubated with VWF exhibited minimal
cleavage of VWF as visualized by the appearance of the 140 kDa
and 176 kDa fragments (Figure 8D lane 3). CiGEnC were
stimulated with PMA, histamine or estradiol. Media taken from
these stimulated cells also exhibited weak bands at 140 kDa and
176 kDa (Figure 8D, lane 4 shows media from cells stimulated
with estradiol), albeit not more than media from unstimulated
cells. These experiments were not carried out using media from
HMVEC.
Taken together, these results indicate that active ADAMTS13 is
present inside glomerular endothelial cells and a small amount is
secreted into the cell media but the activity detected in the
medium was very low.
Figure 3. ADAMTS13 mRNA expression in cultured endothelial cells. ADAMTS13 gene transcripts in endothelial cells were detected by real-
time PCR. A. Using the probe against exons 28–29 the amplification plot indicates detectable ADAMTS13 mRNA levels in CiGEnC and HMVEC cells.
Human kidney (HK) and human liver (HL) were used as the positive controls. No template control (NTC) and CHO cells were used as the negative
controls and showed no amplification. B. The housekeeping gene 18S, which was expressed at comparable levels in all samples, was used to
standardize the data. The upper limit of the boxes depicts the means and bars are standard error of the mean from three separate cell culture
experiments.
doi:10.1371/journal.pone.0021587.g003
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MMP9 expression in cultured endothelial cells
MMP9 has been shown to cleave VWF near the Tyr1606-
Met1605 cleavage site for ADAMTS13 [9]. Using flow cytometry
no MMP9 expression was detected either in CiGEnC or HMVEC
cells (Figure 9A–9B). The control antibody did not exhibit any
signal (Figure 9C–9D). As a positive control for antibody-binding
Figure 4. Detection ofADAMTS13 in cultured endothelial cells by flow cytometry. ADAMTS13 protein was detected in CiGEnC (Panels A–
D) using A10 monoclonal antibody (panel A) and SU19 polyclonal antibody (panel B). The control antibodies, mouse IgG2b-k (panel C) and rabbit IgG
(panel D) did not bind to any cells. HMVEC showed similar results (Panels E–H). Reproducible results were obtained from two different experiments.
doi:10.1371/journal.pone.0021587.g004
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88% of the neutrophil population demonstrated labeling but no
staining of the neutrophil population was observed with the
control antibody (data not shown).
Discussion
In this study we show that glomerular endothelial cells are
capable of producing biologically active ADAMTS13, and that
when ADAMTS13 is lacking, as in the ADAMTS13-deficient
mouse, the glomerular capillary vessel wall is thickened and
irregular. We presume that deposits of plasma proteins, such as
VWF, contribute to platelet deposition along capillaries, as shown
by electron microscopy. ADAMTS13, in plasma and on the
surface of endothelial cells, will cleave ULVWF at the surface of
endothelial cells and prevent the accumulation of platelets on the
glomerular capillary endothelium.
Figure 5. ADAMTS13 expression detected intracellularly by immunofluorescence. ADAMTS13 protein expression was investigated in
CiGEnC (panels A–B) and HMVEC (panels C–D). ADAMTS13 was detected in CiGEnC using SU19 polyclonal antibody (panel A). The SU19 antibody was
pre-incubated with blocking peptide resulting in marked signal reduction (panel B) in which FITC labeling of ADAMTS13 was abolished and blue DAPI
labeling marked cell nuclei. HMVEC cells showed similar results staining positively for ADAMTS13 with the polyclonal SU19 antibody (C). SU19
blocking experiments resulted in marked decrease in signal intensity (D). Reproducible results were achieved in at least six separate cell experiments
from three different passages. All images are at 400x magnification.
doi:10.1371/journal.pone.0021587.g005
Figure 6. ADAMTS13 is secreted into the media. Recombinant
ADAMTS13 showed a band at 150 kDa under non-reducing conditions
(lane 1, the positive control) and control medium did not show any
band (lane 2). Media from CiGEnC and HMVEC exhibited similar bands
at approximately 150 kDa (lanes 3 and 4, respectively). Reproducible
results were obtained from four different experiments.
doi:10.1371/journal.pone.0021587.g006
Figure 7. ADAMTS13 activity depicted by the VWF multimer
structure. Endothelial cell lysates were incubated with purified VWF.
Cell buffer incubated with VWF was used as the negative control and
showed high molecular weight VWF multimers (lanes 1 and 3). CiGEnC
and HMVEC lysates showed marked cleavage of VWF multimers (lanes 2
and 4, respectively). The two panels were run on separate gels but
within each panel samples were run on the same gel. Reproducible
results were obtained from three separate experiments.
doi:10.1371/journal.pone.0021587.g007
ADAMTS13 in Glomerular Endothelial Cells
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ADAMTS13 cleaves ULVWFwhen it is bound to the endothelial
cell [22]. The interaction between ADAMTS13 and ULVWF
attains physiological importance in the setting of endothelial cell
injury. ADAMTS13-deficiency in itself is not sufficient for the
development of thrombocytopenia as shown in the ADAMTS13-
deficient mouse in which platelet counts were normal and thrombi
were not visualized in the kidneys [21]. Introducing the CASA/Rk
background enhanced the susceptibility to develop TTP. These
mice developed thrombocytopenia and VWF-rich thrombi in the
kidney. The pathological lesion was more pronounced in the
presence of endothelial injury induced by Shiga toxin [21]. The role
of VWF was conclusively shown by generating ADAMTS13- and
VWF-deficient mice [23] which were protected from Shiga toxin-
induced injury. The ADAMT13-deficient mouse has a propensity
to platelet deposition on the irregular surface of glomerular
endothelial cells, as shown here, and would thus be more susceptible
to develop thrombi and consumptive thrombocytopenia during
endothelial injury than the wild-type mouse.
ADAMTS13 synthesis by endothelial cells has been previously
shown using human umbilical vein endothelial cells, human
umbilical artery endothelial cells [15], human aortic endothelial
cells and an endothelium-derived cell-line (ECV304) [14]. Taken
together with the results presented herein, showing ADAMTS13
production in microvascular endothelial cells, including glomer-
ular endothelial cells, the production of ADAMTS13 by the
endothelium may constitute a major source of ADAMTS13
present on vessel walls. Plasma ADAMTS13 may presumably be
pooled from several sources including the stellate cells of the liver
[13] as well as endothelial cells lining the vasculature [14,15]. This
may explain why patients with TTP respond to plasma therapy
which replaces ADAMTS13 deficient in plasma [24], which in the
normal population could originate from the endothelium.
ADAMTS13 in the circulation cleaves VWF multimers and
prevents the formation of thrombi on the vascular endothelium
[25]. High shear stress in the glomerular capillaries may require an
additional protective mechanism and we speculate that the
synthesis and secretion of bioactive ADAMTS13 in the glomerular
endothelium may contribute a local protective effect on the
glomerular endothelial cell surface.
Previous studies have shown that ADAMTS13 was secreted
from endothelial cells to the medium [14,15] and that secreted
protease was active [14]. Extracellular ADAMTS13 was demon-
strated in the medium of glomerular endothelial cells in the
current study. Bioactivity in the cell medium was, however, very
low. Although there are differences between results obtained using
in vitro cultured cells and in vivo physiological conditions, we
assume, based on these results, that glomerular endothelial cells
secrete active ADAMTS13 in vivo.
In addition to ADAMTS13, four other proteases, mainly
secreted from leukocytes, are capable of cleaving VWF at or near
the same peptide bond as ADAMTS13: elastase, proteinase 3,
cathepsin G and MMP9 [9]. The first three proteases mentioned
are serine proteases and would be inhibited by the protease
inhibitor cocktail used in this study. MMP9 cleaves VWF at the
M1606-V1607 bond [9]. It is, like ADAMTS13, a metalloproteinase
and would not be inhibited by the cocktail inhibitor. For this
reason we checked for MMP9 production in the CiGEnC or
HMVEC. MMP9 could not be detected by flow cytometry. This
result is supported by a previous study performed on murine
glomerular endothelial cells which showed undetectable MMP9
Figure 8. VWF cleavage by endothelial cell lysates depicted by immunoblotting. A. Recombinant ADAMTS13 cleaves the A2 domain of
VWF whereby 176 kDa and 140 kDa bands appear (lane 1). Full-length VWF is depicted by an arrow. Cell buffer, incubated with VWF and used as the
negative control, did not exhibit the cleavage fragments (lane 2). CiGEnC cell lysate exhibited VWF cleaving activity as shown by the presence of
similar cleavage fragments (lane 3) which were inhibited by 20 mM EDTA (lane 4). HMVEC lysate also showed the two breakdown products (lane 5)
which were partially inhibited by EDTA (lane 6). B. Immunoadsorption of ADAMTS13 inhibited VWF cleaving activity. Recombinant ADAMTS13
showed the two cleavage fragments (lane 1) and the cleaving activity was abrogated by removal of ADAMTS13 (lane 2). CiGEnC cell lysate also
induced VWF cleavage (lane 3) which was inhibited by immunoadsorption of ADAMTS13 from the lysate (lane 4). Experiments were carried out three
times with reproducible results. C. VWF cleavage products were derived from exogenous VWF. Exogenous VWF was added to rADAMTS13 resulting in
two cleavage products (lane 1). CiGEnC lysate, without added exogenous VWF, did not show cleavage bands but exhibited a weak band
corresponding to full-length VWF (lane 2). When purified exogenous VWF was added to CiGEnC lysates VWF cleavage was demonstrated (lane 3). D.
Recombinant ADAMTS13 cleaves exogenously added VWF in cell medium (that was not in contact with endothelial cells, lane 1). Cell medium (that
had not been exposed to cells) without added ADAMTS13 exhibited full-length VWF and a very weak band at 176 kDa (lane 2). Cell medium derived
from unstimulated CiGEnC exhibited a stronger band at 176 kDa and a weak band at 140 kDa (lane 3). Cell medium derived from CiGEnC stimulated
with estradiol exhibited a band at 176 kDa and a weak band at 140 kDa (lane 4). All lanes were run on the same gel. Experiments were carried out
twice with reproducible results.
doi:10.1371/journal.pone.0021587.g008
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mRNA levels and very low protease levels in unstimulated cells
[26]. In addition, MMP9 would be inactivated by chemical
denaturants such as urea [9] which was used in the dialysis step of
the activity assay described here. Furthermore, we could show that
the VWF-cleaving activity in CiGEnC or HMVEC was
specifically related to ADAMTS13 as it was markedly decreased
when ADAMTS13 was immunoadsorbed using a highly specific
antibody [19]. Thus we conclude that the VWF cleavage detected
in this study is mainly related to ADAMTS13 activity.
In summary, this study shows that human glomerular endothelial
cells and microvascular endothelial cells produce bioactive
ADAMTS13 which may both contribute to the pool of circulatory
ADAMTS13 as well as prevent thrombotic events from occurring
on the endothelial cell surface. The glomerular capillaries have a
unique form of hemodynamics surrounding vessel lumina with high
tensile forces. The phenotypic finding of platelet deposits along the
vascular wall in the ADAMTS13-deficient mice suggests that
ADAMTS13 prevents platelet deposition on ULVWF multimers
even under basal conditions. High shear forces and endothelial
damage would promote a prothrombic state in the glomerular
vasculature. ADAMTS13 at the surface of the glomerular
endothelial cell would be expected to exert a local protective effect
which could be crucial at sites of endothelial cell damage.
Methods
Mouse tissue
Renal sections from ADAMTS13 wild-type mice, Adamts13+/+
(n = 5), and ADAMTS13-deficient mice, Adamts132/2 (n = 5),
were used. These mice have been previously described [21,27].
Two mice in each group were generated on a mixed genetic
background 129X1/SvJ and C57BL/6J [21] and the other three
mice were a cross between C57BL/6J and CAST/Ei [27]. Animal
studies were carried out with the approval of the animal ethics
committee of the University of Michigan and University of Iowa.
Paraffin-embedded mouse kidneys were prepared as previously
described [28,29].
Immunohistochemistry for detection of ADAMTS13 in
murine renal tissue
Immunohistochemistry was performed on murine renal tissue to
determine ADAMTS13 expression according to a previously
described method [19]. ADAMTS13 was detected using poly-
clonal chicken-415 anti-mouse ADAMTS13 IgY (directed against
a sequence after the second CUB domain) at 1.25 mg/ml. Chicken
IgY (Jackson Immuno Research, Suffolk, UK) was used as the
negative control. The signal was detected using rabbit anti-
chicken/turkey IgY: HRP (1:250, H+L, Invitrogen, San Fran-
cisco). Specificity of the secondary antibodies used was tested by
omitting the primary antibodies. Slides were examined by light
microscope (Axiostar Zeiss, mounted with an AxioCam MRc5
camera; Carl Zeiss, Go¨ttingen, Germany). Positive signal stained
brown.
Scanning electron microscopy of mouse kidney
Paraffin-embedded murine renal sections were mounted onto
glass slides as above. Slides were prepared as previously described
[30] and cut using a diamond knife. Sections were mounted on to
Figure 9. Lack of detectable MMP9 in the endothelial cells. MMP9 protein was not detected in either CiGEnC (panel A) or HMVEC (panel B)
using mouse anti-human MMP9 antibody investigated by flow cytometry. The control antibody was negative (panels C and D). Results were
reproduced in two separate experiments.
doi:10.1371/journal.pone.0021587.g009
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aluminum stubs and coated with a 30 nm layer of gold.
Glomerular capillary wall thickness was assessed by quantifying
capillary walls in 30 glomerular profiles from each mouse.
Immunoelectron microscopy was performed as previously
described [31]. Platelets were detected with polyclonal goat
anti-human integrin-b3 antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) at 1:800, which showed cross-reactivity with
mouse protein [32]. Normal goat IgG was used as the control
antibody (Santa Cruz Biotechnology). Gold-conjugated rabbit
anti-goat IgG (20 nm; BB International, Cardiff, UK) at 1:20 was
used as the secondary antibody. Immunolabelled tissues were
coated with a thin layer of carbon instead of gold prior to
microscopy. Platelet deposits were quantified by counting the
number of platelets/mm2 in 30 glomeruli/mouse. Tissues were
scanned using a JEOL JSM-350 scanning electron microscope
(JEOL Ltd., Tokyo, Japan) at an acceleration voltage of 5 kV and
a working distance of 10 mm.
Culture of endothelial cells
Conditionally immortalized human glomerular endothelial cells
(CiGEnC) were cultured as described [33] and used at passage 24-
36. Cells were grown in endothelial growth medium 2 -
microvascular (EGM2-MV) supplemented with growth factors as
supplied and 5% fetal bovine serum (all from Lonza, Walkersville,
MD) and 1x penicillin/streptomycin (PAA Laboratories Gmbh,
Pasching, Austria). Cells were grown to confluence at the
permissive temperature of 33uC and then allowed to differentiate
for at least 14 days at the non-permissive temperature of 37uC.
Human dermal microvascular endothelial cells (HMVEC, Cell
Application Inc, San Diego, CA) at passage 3–9 were grown
according to the manufacturer’s instructions in the same medium.
As a negative control for ADAMTS13 synthesis, Chinese Hamster
Ovary (CHO) cells were grown in D-MEM supplemented with 1x
penicillin/streptomycin, 1x non-essential amino acids and 10%
fetal bovine serum (all from PAA Laboratories, Pasching, Austria).
Cells were cultured in culture flasks (TPP AG, Trasadingen,
Switzerland) for collection of RNA, medium, lysates and for flow
cytometry experiments, and on chamber slides (Nunc, Roskilde,
Denmark) for immunofluorescence. For experiments designed to
detect ADAMTS13 mRNA, protein and activity, cells were
washed with Dulbecco’s phosphate buffered saline (PAA Labora-
tories) and incubated for 24 hours with the respective medium as
above, but without serum.
In certain experiments, designed to determine ADAMTS13
activity in cell medium, CiGEnC and HMVEC cells were
stimulated with various agonists. After 24 hrs of incubation with
serum free medium, cells were stimulated with phorbol-12-
myristate-13-acetate (PMA, Sigma–Aldrich, St Louis, MO) at
500 nM for 1 hr or with histamine 100 mM (Sigma-Aldrich) [34]
for 15 min, alternatively with estradiol 1 nM (Sigma-Aldrich) [35]
for a further 24 hrs. As a positive control for cell stimulation VWF
release was measured in cell media by ELISA as described [36].
Of the stimulants used, only histamine exhibited a 2-fold increase
in VWF release.
Cell media were collected in 1x Complete EDTA-free protease
inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) and
centrifuged to remove cell debris. Media were concentrated 100-
fold using Amicon ultracentrifugal filter (Ultracel-50K, Millipore,
Cork, Ireland). Cells were washed, detached by trypsinization,
washed and resuspended in cell buffer (10 mM Tris, 150 mM
NaCl, pH 7.4), supplemented with 1x Complete EDTA-free
protease inhibitor cocktail, at 0.7216106 cells/100 ml cell buffer.
Cells were lysed by repeated freezing and thawing followed by
sonication (Grants Instruments, Cambridge, Royston, UK) and
centrifuged to remove the debris [20]. Media and lysates were
frozen at 280uC until assayed.
Real-time PCR for ADAMTS13 in endothelial cells
RNA was isolated using RNeasy mini kit (Qiagen Gmbh,
Hilden, Germany) and reverse transcribed using TaqManH Gold
RT-PCR Kit (Applied Biosystems, Carlsbad, CA) as previously
described [19]. ADAMTS13 gene transcripts were identified by
real-time PCR (ABI prism 7000; Applied Biosystems) with a probe
directed against exons 28–29 (translating into part of the second
CUB domain; Applied Biosystems, assay Id Hs00260148_ml).
Normal kidney RNA pooled from 14 individuals as well as normal
liver RNA (BD Biosciences Clontech, Palo Alto, CA) were used as
positive controls [20]. CHO cell RNA was used as the negative
control [15] as well as a no-template control. 18S ribosomal RNA
(Applied Biosystems, assay Id: Hs99999901_s1) was used to
standardize the data.
Flow cytometry for detection of ADAMTS13 and MMP9
ADAMTS13 detection within cells was carried out using flow
cytometry. CiGEnC and HMVEC cells were washed with Hanks’
balanced salt solution (HBSS) and detached with trypsin-EDTA
(both from PAA Laboratories). 36105 cells/ml cells were fixed in
1% paraformaldehyde (Sigma–Aldrich) for 30 min at room
temperature, washed with HBSS and centrifuged at 200 g for
5 min. The cell pellet was then incubated with A10 monoclonal
antibody (mouse anti-human ADAMTS13 IgG2b-k against the
disintegrin domain [13]) at 20 mg/ml or SU19 polyclonal rabbit
IgG anti-human ADAMTS13 at 10 mg/ml (directed against a
sequence in the CUB2 domain [37]) for 20 min. The antibodies
were diluted with 0.3% Triton X-100 (ICN Biomedicals, Aurora,
Ohio) in phosphate-buffered-saline (PBS, Medicago AB, Uppsala,
Sweden) and the incubation steps were carried out at room
temperature. Cells were then washed with HBSS and incubated
with rabbit anti-mouse IgG:phycoerythrin (PE) at 1:100 or swine
anti-rabbit IgG:fluorescein isothiocyanate (FITC) at 1:40 (both
from Dako, Glostrup, Denmark) for 20 min. Normal mouse
IgG2b-k (Abcam, Cambridge, UK) and normal rabbit IgG
(Antibody AB, Lund, Sweden) were used as the negative control
antibodies.
MMP9 expression was studied using mouse anti-human MMP9
(Santa Cruz Biotechnology, Santa Cruz, CA) at 10 mg/ml diluted
with 0.3% Triton X-100 in PBS. Mouse IgG1 was the isotype
control and rabbit anti-mouse IgG:PE (both from Dako) was the
secondary antibody. Human neutrophils, which produce MMP9
[38], were used as positive control cells. Neutrophils were isolated
from a healthy donor using a one-step density gradient
centrifugation with PolymorphprepH (Nycomed, Oslo, Norway)
as previously described [39].
Antibody binding was analyzed using BD FACSCantoTM II and
FACS Diva software (Becton Dickson Immunocytometry Systems,
San Jose, CA). Cells were identified on the basis of the forward
scatter (FSC) and side scatter (SSC) profile. By setting a gate
around the cells, 1000 events for endothelial cells and 5000 events
for neutrophils were analyzed for PE or FITC fluorescence.
Background fluorescence of the control antibodies was subtracted
in all the experiments. Specificity of the secondary antibodies was
tested by omission of the primary antibodies.
Immunofluorescence for demonstration of ADAMTS13 in
cells
Endothelial cells, grown on chamber slides, were washed and
permeabilized with 0.3% Triton X-100 in PBS and ADAMTS13
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expression was investigated using anti-ADAMTS13 antibodies:
A10 at 5 mg/ml or SU19 at 10 mg/ml, as previously described
[19]. The signal was visualized with goat anti-mouse IgG F(ab)2
FITC 1:20 (Dako) or goat anti-rabbit (H+L) F(ab)2 Alexa-Flour
488 1:150 (Molecular Probes, Eugene, OR). For the A10 antibody,
normal mouse IgG2b-k was the isotype control antibody. In order
to test the specificity of SU19, the antibody was preincubated with
a 50-fold molar surplus of blocking peptide [20]. Specificity of the
secondary antibodies was tested by omitting the primary
antibodies. Cell nuclei were stained with 49, 6-diamidino-2-
phenylindole (DAPI) in the mounting medium (Vector Laborato-
ries, Burlingame, CA).
Immunoblotting for detection of ADAMTS13 in cell
medium
ADAMTS13 expression in the cell media was investigated by
immunoblotting. Cell medium from both endothelial cells, diluted
1:2 in sample buffer (0.01 mol/L Tris buffer, pH 6.8 containing
4% [w/v] sodium dodecyl sulfate [SDS], 8% glycerol [all from
Sigma-Aldrich] and 1% bromophenol blue [LKB Products AB,
Bromma, Sweden]) were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) followed by
immunoblotting under non-reducing conditions, as previously
described [20]. ADAMTS13 was detected with goat anti-human
ADAMTS13 antibody, directed against residues 825-875 located
in fourth Tsp1 (thrombospondin 1)-like domain (BL156, Bethyl
Laboratories, Montgomery, TX, USA) at 2 mg/ml. Rabbit anti-
goat IgG:HRP (Dako) at 1:2000 was used as the secondary
antibody. Purified recombinant ADAMTS13 [20], diluted 1:800
in the above-mentioned buffer was used as the positive control and
serum free control medium was used as negative control. Signal
was detected by chemiluminescence using ECL plus (Amersham
Biosciences, Uppsala, Sweden).
VWF multimer structure analysis
ADAMTS13 activity was analyzed by VWF multimer structure
analysis as previously described [1,19]. Cell lysates were activated
with 10 mmol/l BaCl2 for 30 min at 37uC. VWF (L.F.B., Les Ulis,
France) at 2 U/ml was added and the suspensions were dialyzed
against 1.5 M urea, 5 mM Tris pH 8.3 (both from Sigma-Aldrich)
overnight. Cell buffer was used as the negative control.
Immunoblotting for identification of VWF cleavage
products specific for ADAMTS13
Specific ADAMTS13 activity in lysates and media was further
tested by detection of the 140 kDa and 176 kDa VWF fragments
arising after cleavage at the 1605Tyr-1606Met residues in the A2
domain by SDS-PAGE [8]. Lysates and media were activated as
described for multimer structure analysis and VWF was added.
After dialysis, the samples were diluted 1:2 under reducing
conditions with 2x SDS-PAGE sample buffer (0.125 M Tris, 20%
glycerol, 4% SDS, 2% dithioerythritol, [all from Sigma-Aldrich]
and 0.001% bromofenol blue [LKB products]). Immunoblotting
was carried out using a combination of pooled mouse anti-human
VWF antibody (specific for the 176 kDa fragment) at 1:500 and
mouse M13 antibody anti-human VWF (specific for 140 kDa
fragment) at 1:500 (gifts from Z.Ruggeri, The Scripps Research
Institute, La Jolla, CA) [8]. Goat anti-mouse IgG:HRP (Dako) at
1:2000 was the secondary antibody and detection was carried out
by chemiluminescence. Recombinant ADAMTS13 purified from
cultured HEK293 cells transfected with the pIRESneo2 VCP
HIS-vector encoding the human ADAMTS13 gene [20] was used
as the positive control at 1:50 dilution in cell buffer or control
medium. VWF substrate diluted in cell buffer or cell medium
subject to the same conditions was used as the negative control.
Cell lysates and media were also run without the addition of VWF
to ascertain that VWF cleavage products were solely from
exogenously added VWF. To test for specificity of ADAMTS13
activity cell lysates were pre-incubated with 20 mM EDTA [40] to
block metalloproteinase activity. In addition, ADAMTS13 was
immunoadsorbed by incubation with a 100 molar surplus of SU19
anti-ADAMTS13 antibody followed by incubation with a protein-
A sepharose (Amersham Biosciences, Buckinghamshire, UK) in
order to remove the ADAMTS13-antibody complexes formed.
Statistical analysis
Differences between ADAMTS13 wild-type and deficient mice
with regard to vessel wall thickness and platelet deposits on
capillary walls were assessed by the Mann-Whitney U-test. A P-
value#0.05 was considered significant. Statistical analysis was
performed by GraphPad Prism software (GraphPad software,
Version 5, La Jolla, CA).
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